DYRK1

DYRK1 Related Products (30):

By Type:	Pan (17) Selective (6)

Cat. No.	Product Name	Effect	Purity

HY-12277

AZ191	Inhibitor	99.98%
AZ191 is a potent inhibitor that selectively inhibits DYRK1B with IC₅₀ of 17 nM.

HY-112296

T025	Inhibitor	98.84%
T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC₅₀ values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research.

HY-132308

DYRK1-IN-1	Inhibitor	99.62%
DYRK1-IN-1 is a highly selective and ligand-efficient DYRK1A inhibitor. DYRK1-IN-1 inhibits DYRK1A phosphorylation activity with an IC₅₀ value of 220 nM. DYRK1-IN-1 can be used for the research of central nervous system penetrant DYRK1A chemical probe.

HY-142295

GNF2133	Inhibitor	98.49%
GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes.

HY-U00439A

Protein kinase inhibitor 1 hydrochloride	Inhibitor	≥98.0%
Protein kinase inhibitor 1 hydrochloride is a potent HIPK2 inhibitor, with IC₅₀s of 136 and 74 nM for HIPK1 and HIPK2, and a K_d of 9.5 nM for HIPK2.

HY-157995

Dyrk1A-IN-7	Inhibitor
Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC₅₀ value of DYRK1A is 28 nM. For CLK2, K_d is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases.

HY-156816

ON 108600	Inhibitor	99.73%
ON 108600 is a inhibitor for CK2 (Casein Kinase2)/TNIK/DYRK1 , with the IC₅₀s for DYRK1A/DYRKB, DYRK2, CK2α1/CK2α2, and TNIK of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM, respectively. ON 108600 has antitumor activity.

HY-115677

ILK-IN-3	Inhibitor	99.62%
ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model.

HY-N0737

Harmine hydrochloride	Inhibitor	99.93%
Harmine Hydrochloride (Telepathine Hydrochloride) is a natural DYRK inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT_2A serotonin receptor, with an K_i of 397 nM.

HY-111379

EHT 5372	Inhibitor	98.12%
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively.

HY-15951

ML167	Inhibitor	98.62%
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC₅₀ of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B.

HY-117391

AZ-Dyrk1B-33	Inhibitor	99.95%
AZ-Dyrk1B-33 is a potent and selective Dyrk1B kinase inhibitor, with an IC₅₀ of 7 nM.

HY-146221

Dyrk1A-IN-5	Inhibitor	98.56%
Dyrk1A-IN-5 (compound 5j) is a potent and selective DYRK1A inhibitor, with an IC₅₀ of 6 nM. Dyrk1A-IN-5 dose-dependently reduces the phosphorylation of Thr434 in SF3B1, with an IC₅₀ of 0.5 μM. Dyrk1A-IN-5 inhibits phosphorylation of tau at Thr212, with an IC₅₀ of 2.1 μM. Dyrk1A-IN-5 can be used for Down syndrome research.

HY-12828A

KH-CB20	Inhibitor	99.80%
KH-CB20, an E/Z mixture, is a potent and selective inhibitor of CLK1 and the closely related isoform CLK4, with an IC₅₀ of 16.5 nM for CLK1. KH-CB20 can also inhibit DYRK1A (IC₅₀=57.8 nM) and CLK3 (IC₅₀=488 nM).

HY-129492

GNF4877	Inhibitor	99.32%
GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC₅₀s of 6 nM and 16 nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC₅₀ of 0.66 μM for mouse β (R7T1) cells).

HY-149262

CLK1-IN-3	Inhibitor	98.03%
CLK1-IN-3 (compound 10ad) is a potent and selective Clk1 inhibitor, with an IC₅₀ of 5 nM and over 300-fold selectivity for Dyrk1A. CLK1-IN-3 also shows a relatively potent inhibition against Clk2 and Clk4, with IC₅₀ values of 42 and 108 nM, respectively. CLK1-IN-3 potently induces autophagy in vitro. CLK1-IN-3 can be used for acute liver injury (ALI) research.

HY-147066

Dyrk1A-IN-4	Inhibitor	99.90%
Dyrk1A-IN-4 (compound 48) is a potent and orally active DYRK1A and DYRK2 inhibitor with IC₅₀s of 2 nM and 6 nM, respectively. Dyrk1A-IN-4 has anticancer effects.

HY-128758

DYRKs-IN-1	Inhibitor
DYRKs-IN-1 is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 has antitumor activity.

HY-128758A

DYRKs-IN-1 hydrochloride	Inhibitor	99.70%
DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity.

HY-101029A

MBM-55S	Inhibitor
MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC₅₀=5.4 nM) and DYRK1a (IC₅₀=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice.

Name
Email *

	Sorry, but the email address you supplied was invalid.